A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Rectal AdenocarcinomaNon Metastatic
Interventions
PROCEDURE

Sparing Approach

Accurate staging with Pelvic MRI, CT scan, PET total body have to be performed before local excision in order to exclude false positive mesorectal lymph nodes. Subsequent Wait and See (W\&S) approach could be proposed.

PROCEDURE

experimental chemoradiotherapy

Participants with cT2N0 rectal tumors are typically candidates for upfront surgical resection. The investigators propose an alternative approach based on experimental chemoradiotherapy (spCRT). Literature suggests that pathologic complete response (pCR) rates after CRT are significantly higher than the 25% described for intermediate-advanced tumors. The investigators will assess clinical complete response (cCR) or complete metabolic response (cMR) through a multidisciplinary restaging process, including MRI, PET, thorax-abdomen CT scan, ERUS, and rectoscopy. In participants achieving cCR or cMR, a Watch and Wait (W\&S) strategy or Local Excision/Transanal Minimally Invasive Surgery (LE/TAMIS) may be proposed to avoid the physical and psychological consequences of major surgery, followed by a rigorous surveillance program.

PROCEDURE

Standard Chemotherapy

Tumors will be initially treated with standard CRT (stCRT). Patients who reach cCR-cMR at restaging they are already candidates to sparing approaches with W\&S/LE/TAMIS according to Multicentric Resarch Study Protocol

Trial Locations (1)

10060

RECRUITING

Department of Surgical Oncology - FPO-IRCCS Institute for Cancer Research and Treatment, Candiolo

All Listed Sponsors
lead

Fondazione del Piemonte per l'Oncologia

OTHER